TRANSLATE

Welcome to Our Parkinson's Place


I copy news articles pertaining to research, news and information for Parkinson's disease, Dementia, the Brain, Depression and Parkinson's with Dystonia. I also post about Fundraising for Parkinson's disease and events. I try to be up-to-date as possible. I have Parkinson's
diseases as well and thought it would be nice to have a place where
updated news is in one place. That is why I began this blog.
I am not responsible for it's contents, I am just a copier of information searched on the computer. Please understand the copies are just that, copies and at times, I am unable to enlarge the wording or keep it uniformed as I wish. This is for you to read and to always keep an open mind.
Please discuss this with your doctor, should you have any questions, or concerns. Never do anything without talking to your doctor. I do not make any money from this website. I volunteer my time to help all of us to be informed. Please no advertisers. This is a free site for all.
Thank you.


Friday, April 28, 2017

New spin out to investigate decade’s worth of neurological research

April 28, 2017



A virtual biotech company has been launched by Parkinson’s UK and the University of Sheffield to create a new novel treatment for the neurological disease.  
The company, Keapstone Therapeutics, will aim to further develop more than decade’s worth of research at the University of Sheffield that could trigger the body’s defence system to protect cells from oxidative stress. There is a wide array of evidence that suggests that oxidative stress may cause or contribute to Parkinson’s.
Director of Research at Parkinson’s UK, Arthur Roach, said: “Due to the funding gap in early stage drug discovery, there are promising scientific breakthroughs for Parkinson’s happening every day that are not being picked up and developed by commercial companies.
“This major new programme of work will allow us to act in a similar way to a small biotech company. However, unlike a commercial company, our primary goal is the creation of new treatments to improve the lives of people with Parkinson’s, regardless of commercial considerations.”
Oxidative stress has been linked to a build-up of free radicals and the spinout will fund Synature Discovery to optimise these small molecules to prevent the interaction between two proteins – Kelch-like ECH-associated protein-1 (KEAP1) and Nuclear factor (erythroid-derived 2)-like 2 (Nrf2). These will increase the survival of neurons in not only Parkinson’s, but also motor neurone disease.
Dr Richard Mead, from Keapstone Therapeutics and one of the scientists who had been working on these small molecules, said: “We are very excited about this new partnership with Parkinson’s UK.  It is a great opportunity for us to pursue a novel drug discovery programme for both Parkinson’s and MND.  We will now progress these molecules through the next stage of drug development with Sygnature Discovery and Peak Proteins (a specialist protein laboratory).”

No comments:

Post a Comment